AI illustration · not actual product photoDetails from the source.
Source-listed BPC 10mg + TB 10mg (SKU BB20): 20mg*10vials. PriceList(1).pdf lists 152 per 10 vials but does not specify currency; the website displays $152 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- BB20
- Source specification
- 20mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Catalogue family of peptide-labeled blends. Source-listed labels and details: BB10, “BPC + TB,” specification *10vials, price 89 per 10 vials; BB20, “BPC + TB,” specification *10vials, price 152 per 10 vials. PriceList(1).pdf does not state a currency. These labels are preserved verbatim. BPC-157 is a peptide studied independently, but the blend label “TB” does not identify an exact molecule, sequence, salt, or formulation. These are source catalogue claims, not verification of vial contents.
Biological mechanism
Preclinical studies of BPC-157 report effects involving VEGFR2, Akt/eNOS and nitric-oxide signaling, ERK1/2, angiogenesis, and tissue repair. These are proposed mechanisms drawn from laboratory and animal findings, not validated mechanisms of benefit in humans. The blend’s “TB” component is not chemically defined by the source, so a mechanism or interaction for the combination cannot be established.
Research focus
BPC-157 alone has mainly been studied in laboratory and animal models of musculoskeletal soft-tissue injury, tendon and muscle repair, and wound healing. FDA’s 2026 review evaluated nominated TB-500-related substances in a wound-healing context, but this does not identify the “TB” in these SKUs. A registered Phase 2 trial investigates BPC-157 alone for acute hamstring strain; it is not a study of BB10, BB20, or the blend.
Potential applications in the evidence
The evidence supports describing only areas under investigation, not benefits: standalone BPC-157 is explored in preclinical tissue-repair models, and a BPC-157-only hamstring-strain trial is registered. FDA reviewed TB-500-related nominations in a proposed wound-healing context. No direct clinical evidence for this BPC + TB combination was identified, and standalone findings do not establish an application for the blend.
Human evidence
Human evidence for BPC-157 is very limited. A 2025 review identified only three human pilot studies across different settings. One 2025 intravenous pilot reported no adverse effects or notable measured laboratory changes in two participants, but this cannot establish safety or efficacy. A registered Phase 2 hamstring trial showed recruiting status and no results posted in the record reviewed. No human study of BB10, BB20, or the exact BPC-plus-“TB” combination was identified. FDA reported it had not identified human exposure data for drug products containing the specific TB-500 fragment it reviewed. Research on full-length recombinant thymosin beta-4 or another fragment cannot be assigned to this unidentified ingredient.
Known and potential effects
The two-participant BPC-157 pilot reported no adverse effects; this very small study cannot rule out uncommon, delayed, or formulation-specific harms. FDA raised potential immunogenicity concerns for injectable BPC-157 in connection with aggregation and peptide-related impurities. For the specific TB-500 fragment FDA reviewed, FDA cited a lack of human exposure data and potential immunogenicity risks, including aggregation and impurities. These are concerns about nominated substances and proposed compounded products, not demonstrated effects of BB10 or BB20. No blend-specific adverse-effect profile was identified.
Safety and contraindications
The exact composition, manufacturer, lot, formulation, route, and quality of these catalogue vials are not supplied. FDA’s BPC-157 and TB-500 reviews describe concerns about uncertain identity or characterization, peptide-related impurities, aggregation, and possible immunogenicity for injectable forms. Those findings do not verify the contents or status of these SKUs. Specific contraindications for this blend cannot be verified from available documents or human evidence; its risks therefore remain unknown, and no safety guarantee is supported.
U.S. FDA / regulatory status
No FDA approval record for the exact BB10 or BB20 vial or this exact combination was verified in the sources reviewed. FDA’s 2026 advisory-committee materials considered BPC-157-related and TB-500-related bulk substances in the separate process for possible inclusion on the 503A compounding bulk-substances list. FDA briefing documents recommended against inclusion of the reviewed substances; the committee process is advisory and distinct from marketing approval. Neither that review nor any component-level evidence establishes approval of these supplier-specific vials. Manufacturer, lot, formulation source, jurisdiction, and authorization documents were not provided, so exact-item approval cannot be verified. Do not label the items compounded or research-only without documentation establishing that status.
Evidence limitations
There is no identified direct clinical evidence for the combination. BPC-157 evidence is predominantly preclinical, with only a few small human pilot studies and an ongoing registered trial without results. “TB” is ambiguous; research on a named TB-500 fragment or full-length thymosin beta-4 cannot be attributed to this catalogue item. The provided PriceList(1).pdf is the only source for listed names, strengths, and prices; it omits currency and does not identify the product’s manufacturer, lot, formulation source, jurisdiction, chemical composition, or approval status.
Supporting sources
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine; PubMed Central/NLM · Peer-reviewed narrative review. Supports: BPC-157 peptide identity, proposed pathways, predominance of preclinical research, and the limited human evidence base.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine; PubMed/NLM · Primary human pilot study record. Supports: Two-participant BPC-157 pilot and its reported observations; supports the explicit limitation that it cannot establish safety or efficacy.
- BPC 157 for Acute Hamstring Muscle Strain Repair ClinicalTrials.gov; U.S. National Library of Medicine · Clinical trial registry. Supports: Registered BPC-157-only Phase 2 hamstring trial, its recruiting status and absence of posted results in the record reviewed; not evidence for the blend.
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances U.S. Food and Drug Administration · FDA advisory committee briefing document. Supports: FDA discussion of BPC-157 identity/characterization, injectable immunogenicity concerns, and proposed 503A bulk-list evaluation; not approval of these SKUs.
- FDA Briefing Document for TB-500-Related Bulk Drug Substances U.S. Food and Drug Administration · FDA advisory committee briefing document. Supports: FDA description of a specific TB-500 fragment, ambiguity in the common name, absence of identified human exposure data for the reviewed fragment, safety concerns, and its compounding-list evaluation.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration · FDA advisory committee meeting page. Supports: FDA’s 2026 committee agenda for BPC-157- and TB-500-related substances and explanation that committee recommendations are nonbinding; distinguishes compounding-list review from approval.